Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04637698
Other study ID # BH-OH2-006
Secondary ID
Status Terminated
Phase Phase 1/Phase 2
First received
Last updated
Start date February 2, 2021
Est. completion date May 4, 2023

Study information

Verified date November 2023
Source Binhui Biopharmaceutical Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase Ib/II study evaluates the safety and efficacy of OH2 in patients with locally advanced/metastatic pancreatic cancer who have failed first-line standard treatment. OH2 is an oncolytic virus developed upon genetic modifications of the herpes simplex virus type 2 strain HG52, allowing the virus to selectively replicate in tumors. Meanwhile, the delivery of the gene encoding human granulocyte macrophage colony-stimulating factor (GM-CSF) may induce a more potent antitumor immune response.


Description:

OH2 injection ≤ 4 mL, administered by intratumoral injection of EUS-FNA, administered on the first day of the first cycle, every 3 weeks thereafter, administered on the 1st day of each cycle ± 3 days, continuous administration does not more than 6 treatment cycles.


Recruitment information / eligibility

Status Terminated
Enrollment 5
Est. completion date May 4, 2023
Est. primary completion date May 4, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. The non-operative stage III or stage IV locally advanced or metastatic pancreatic cancer patients with clear diagnosis by pathology and/ or cytology. 2. Life expectancy >3 months. 3. Have received at least first-line or more systemic chemotherapy and failed. The definition of failure: Receiving first-line systemic chemotherapy means having used first-line chemotherapy such as gemcitabine, or tigeo capsule, or albumin paclitaxel, or liposomal irinotecan, or FOLFINOX.During or after treatment, the disease progression or toxic side effects are intolerable, and there must be imaging evidence or clinical evidence to prove the disease progression. For neoadjuvant/adjuvant therapy (chemotherapy or radiotherapy), if disease progression occurs during treatment or within 6 months after stopping treatment, it should be counted as a failure of first-line treatment; 4. Prior anti-tumor treatment including systemic, radical/extensive radiotherapy, targeted therapy, immunotherapy was over 28 days; 5. According to RECIST version 1.1, there is at least one measurable lesion that is suitable for intratumoral injection. The measured non-nodular lesions is defined as the longest diameter = 10 mm . For lymph node lesions, the short diameter is = 15 mm.If the measurable lesions located in the radiation field of previous radiotherapy or after local treatment are confirmed to have progressed, they can also be selected as target lesions. 6. General physical condition score ECOG 0 = 2 (including boundary value); 7. a) Blood routine: ANC=1.5×10^9/L, PLT=80×10^9/L, Hb=9.0 g/dL.Note: 14 days before the examination, it is not allowed to use any blood components, cell growth factors and other interventions to make the indicators reach the normal range;b) Liver function: TBIL= 1.5 times the upper limit of the normal value, ALB=30 g/L, ALT and AST = 2.5 times the upper limit of normal value; The value of patients with liver metastasis did not exceed 5 times the upper limit of normal value.; c) Renal function: Scr=1.5 times the upper limit of the normal value,Ccr=50mL/min (Cockcroft-Gault); d) Coagulation function is normal (PT and APPT are within 1.5 times of the upper limit of normal value); 8. Women of childbearing age had a negative pregnancy test result within 7 days before enrollment. Female subjects and their spouses received effective contraceptives during and within 6 months of treatment; 9. Weight=40 kg; 10. Subjects with herpes in the reproductive organs needed three months after the end of herpes. 11. The informed consent was voluntarily signed and the expected compliance was good. Exclusion Criteria: 1. Patients diagnosed with pancreatic cancer without pathology and/ or cytology; 2. The target lesion has received local non-drug therapy (including radiotherapy, physical and/or chemical ablation, etc.), and no imaging disease progression has occurred; 3. Central nervous system metastasis or cancerous meningitis is known to occur. For suspected central nervous system metastasis, head MRI examination is required; 4. Patients with Vater's ampullary carcinoma or biliary adenocarcinoma; 5. Patients with partial or complete intestinal obstruction and complete biliary obstruction that cannot be relieved by active treatment; 6. With more than a moderate amount of ascites, or after conservative medical treatment (such as diuresis, sodium restriction, excluding ascites drainage) for 2 weeks, the ascites still shows a progressive increase; 7. A history of other malignant tumors in the past 5 years, except for the following two cases: a. Other malignant tumors treated by a single operation, achieving 5 consecutive years of disease-free survival; b. Cured skin basal cell carcinoma and cured cervical carcinoma in situ; 8. Pregnant or lactating female; 9. Suffer from severe chronic or active infections, including tuberculosis, syphilis, AIDS (HIV antibody positive); 10. Hypertension that cannot be effectively controlled (defined as systolic/diastolic blood pressure =150/100 mmHg or meeting one of them after treatment with standardized antihypertensive drugs); Angina pectoris or unstable angina pectoris occurred within the last 3 months, myocardial infarction or cardiac insufficiency occurred within 1 year before enrollment (heart function = New York Heart Association NYHA grade II); Severe arrhythmia requiring medical treatment, left ventricular ejection fraction <50%; QTc interval male>450ms, female>470ms; Or there are risk factors for torsade de pointes ventricular tachycardia, such as clinically significant hypokalemia as judged by the investigator; Family history of long QT syndrome or family history of arrhythmia (such as WPW syndrome); Schizophrenia, or history of psychotropic drug abuse; 11. Suffer from acute or chronic active hepatitis (Hepatitis B reference: HbsAg positive and HBV DNA viral load =200IU/mL or =10^3 copies/mL, HCV antibody positive and HCV RNA positive); 12. Received any of the following treatments within a certain period of time before enrollment: a.Received second-level or above surgery within 4 weeks (regardless of tumor-related or not), except for minimally invasive surgery under gastrointestinal endoscope; b. Received extended-range radiotherapy within 4 weeks, or received local-range radiotherapy within 2 weeks; c. Other clinical studies have been taken in the past 4 weeks; d. Received local anti-tumor therapy within 4 weeks; 13. Toxicity caused by previous anti-tumor therapy before the first dose has not yet recovered to NCI CTCAE version 5.0 grade 0 or 1 (excluding hair loss, skin pigmentation, and non-clinically significant and asymptomatic laboratory abnormalities); 14. Known to be allergic or intolerant to OH2 and its excipients; 15. The researchers believe that there is any reason why the patient is not suitable to participate in this trial.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
OH2 injection
Oncolytic Type 2 Herpes Simplex Virus

Locations

Country Name City State
China Chongqing University Cancer Hospital Chongqing Chongqing

Sponsors (1)

Lead Sponsor Collaborator
Binhui Biopharmaceutical Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary The objective response rate of patients with pancreatic cancer receiving OH2 injection. Tumor evaluation is performed according to RECIST1.1 and iRECIST1.1. The assessment result is the number and proportion of subjects with complete response + partial response. 2 years
Secondary Evaluation of safety of OH2 injection in patients with pancreatic cancer. According to the version 5.0 of the National Cancer Institute Common Terminology Criteria for Adverse Events, the adverse events during the entire study period are evaluated. 2 years
Secondary The disease control rate of patients with pancreatic cancer receiving OH2 injection. Tumor evaluation is performed according to RECIST1.1 and iRECIST1.1. The assessment result is the number and proportion of subjects with complete response + partial response + stable disease. 2 years
Secondary The duration of response of patients with pancreatic cancer receiving OH2 injection Tumor evaluation is performed according to RECIST1.1 and iRECIST1.1. The time from the first assessment of complete response or partial response to the first assessment of disease progression or death from any cause. 2 years
Secondary The progression free survival of patients with pancreatic cancer receiving OH2 injection. Tumor evaluation is performed according to RECIST1.1 and iRECIST1.1. Time from start of treatment to disease progression. 2 years
Secondary To evaluate the impact of OH2 in patients with pancreatic cancer on the quality of life Evaluation based on EORTC QLQ-C30. 2 years
See also
  Status Clinical Trial Phase
Completed NCT05305001 - Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Recruiting NCT05497531 - Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers N/A
Recruiting NCT04927780 - Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer Phase 3
Recruiting NCT06054984 - TCR-T Cells in the Treatment of Advanced Pancreatic Cancer Early Phase 1
Recruiting NCT05919537 - Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation Phase 1
Terminated NCT03140670 - Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy Phase 2
Terminated NCT00529113 - Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer Phase 1
Recruiting NCT05168527 - The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients Phase 2
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Recruiting NCT05391126 - GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care N/A
Terminated NCT03300921 - A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer Phase 1
Completed NCT03153410 - Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas Early Phase 1
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2
Recruiting NCT05679583 - Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer Phase 2
Recruiting NCT04183478 - The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer Phase 2/Phase 3
Terminated NCT03600623 - Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer Early Phase 1
Recruiting NCT04584008 - Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics N/A
Recruiting NCT05351983 - Patient-derived Organoids Drug Screen in Pancreatic Cancer N/A
Completed NCT04290364 - Early Palliative Care in Pancreatic Cancer - a Quasi-experimental Study